---
title: "USANA Health Sciences 2Q 2026: Revenue $223.3M, Net loss $(21.4) M, EPS $(1.16) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295833878.md"
description: "USANA Health Sciences reported a Q2 2026 net loss of $21.4M (EPS: -$1.16), reversing prior-year earnings, with revenue declining 5.3% to $223.3M. Core sales dropped due to a 10% customer decline. The company recorded a $29.1M goodwill impairment related to its Hiya acquisition, reflecting revised performance expectations amid operational transitions."
datetime: "2026-08-13T18:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295833878.md)
  - [en](https://longbridge.com/en/news/295833878.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295833878.md)
generator: "portal-rs"
---

# USANA Health Sciences 2Q 2026: Revenue $223.3M, Net loss $(21.4) M, EPS $(1.16) — 10-Q Summary

USANA Health Sciences Inc. reported second-quarter 2026 results with revenue of $223.3M, a year-over-year decline, and a net loss attributable to USANA of $(21.4) M, or diluted EPS of $(1.16), compared with net earnings of $9.7M and diluted EPS of $0.52 in the year-ago quarter.

**Financial Highlights**

-   Revenue: $223.3M for Q2 2026, down from $235.8M in the year-ago quarter ( (5.3%)).
-   Net income: Net loss attributable to USANA of $(21.4) M for Q2 2026, versus net earnings of $9.7M in the year-ago quarter.
-   Diluted EPS: $(1.16) for Q2 2026, versus $0.52 in the year-ago quarter.

**Business Highlights**

-   Revenue trend: Consolidated net sales were down 2.5% year-to-date (six months) and down 5.3% in Q2, driven by declines in Core Nutritional and Hiya.
-   Customer dynamics: Core active Customers declined about 10% year-to-date to roughly 384,000, putting pressure on recurring sales despite a slight rise in average spend.
-   Channel and product shifts: The company is transitioning toward an omni-channel model; Core direct selling remains primary while Hiya grows in subscription and retail, and Rise expanded retail presence with Protein Pop.
-   Margins and costs: Core gross margins were pressured by lower production volumes; Hiya margins improved due to shipping savings and product mix, offset by increased Hiya marketing spend.
-   Operational milestone: USANA completed acquisition of a controlling interest in Hiya in December 2024 and recorded a $29.1M goodwill impairment reflecting a revision to near-term Hiya performance expectations.

Original SEC Filing: USANA HEALTH SCIENCES INC \[ USNA \] - 10-Q - Aug. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [USNA.US](https://longbridge.com/en/quote/USNA.US.md)

## Related News & Research

- [USANA CEO Guest urges people to make service intentional, "find need, then act](https://longbridge.com/en/news/297641623.md)
- [Elizabeth Warren Demands Congress Stop 'Drawn-Out Discussions' on AI and Pass 'Meaningful Regulations' to Protect People](https://longbridge.com/en/news/299545040.md)
- [Kardigan (NASDAQ:KARD) Is In A Good Position To Deliver On Growth Plans](https://longbridge.com/en/news/299528349.md)
- [Germany's IW institute triples growth forecast for 2026](https://longbridge.com/en/news/299543926.md)
- [AIRS Investors Have Opportunity to Join AirSculpt Technologies, Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/299533339.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**